There are nights when we want to dive inward, to sit with our shadows and unpack the soul. And then there are nights when the call is the opposite — when what we really need is to step out of the body for a while, drift somewhere weightless, and let the music carry us. Leap, sold under the suggestive subtitle Pure Escape, leans hard into that second mood. It doesn’t try to teach you anything. It simply opens a door and invites you to fall gently through it.
What It Feels Like
Leap comes on quickly. Within the first ten minutes, a soft tingling spreads across the skin, and by half an hour you’re already drifting. The body grows light, then lighter still, until it almost feels like someone has wrapped a warm blanket around your nervous system. People often describe a sense of weightlessness, a slow disconnect between mind and limbs, like the floor has decided to be a bit more optional than usual.
Visuals are present but quieter than what you’d get on mushrooms or LSD. Edges of objects soften, light takes on a slight shimmer, and depth perception starts to play tricks. Time becomes elastic — minutes stretch into long, glowing intervals, and a single song can feel like an entire emotional arc. Music, in fact, is where Leap really earns its name. Sounds gain dimension, layers reveal themselves, and the line between hearing and feeling thins out.
Mood-wise, the experience is gentler than ketamine. There’s a mild euphoria — described by many as “cozy” rather than ecstatic — and a soft sedation that some compare to the heavy-limbed comfort of cannabis couch lock. Thoughts get loose and meandering, sometimes circling back on themselves in a way that feels almost philosophical. Higher doses tilt the whole thing further, with stronger visual distortions, out-of-body sensations, and the kind of disorientation that demands a quiet room rather than a dance floor.
The full arc lasts longer than ketamine — typically four to six hours, with an afterglow that can linger another six to eight. That extended timeline is one of Leap’s defining features, and worth knowing before you start.
The Molecule Behind the Escape
Leap is built around 2F-NENDCK, also called CanKet or 2-FXE. The name is a mouthful — short for 2-fluoro-N-ethylnordeschloroketamine — but the story is interesting. The compound was first formally identified in 2022 at CanTEST, a drug-checking service in Canberra, Australia, when someone brought in a powder they thought was ketamine. It wasn’t. After analysis by researchers at the Australian National University, the molecule turned out to be a new arylcyclohexylamine, structurally very close to ketamine but with two small twists: a fluorine atom where ketamine has a chlorine, and an N-ethyl group where ketamine has an N-methyl. The nickname CanKet — short for “Canberra ketamine” — stuck.
Those small chemical changes have real consequences. The N-ethyl group makes the molecule more lipophilic, meaning it lingers in tissue longer. That’s the leading explanation for why Leap’s effects stretch out to four to six hours instead of the single hour you’d get from snorted ketamine. The compound is presumed to work the same way as its older cousin — as an NMDA receptor antagonist, gently muting the brain’s main excitatory signal until the connection between body, self, and surroundings goes pleasantly fuzzy.
Arylcyclohexylamines have a long, strange lineage. The family began with PCP back in the 1950s, expanded through ketamine and PCE, and was later picked up by underground chemists searching for novel dissociatives — methoxetamine (MXE) in the 2010s being one of the most famous examples. 2F-NENDCK is the newest branch on that tree, still largely unstudied in formal clinical settings, with most of what we know coming from harm-reduction labs and the careful reports of psychonauts who got there first.
Shayana Shop carries Leap as one of its exclusives. For European explorers, Shayana has been a quietly reliable name in the scene for two decades — the kind of shop that doesn’t just chase trends but tends to a slowly evolving catalog of rarities. Leap fits that pattern. It isn’t a shiny mainstream product. It’s a research chemical with a clear identity, sold to people who already know what they’re getting into.
Set, Setting, and a Few Honest Words
Leap is not a party drug, even though some users do enjoy it socially. Its center of gravity is closer to a long, slow indoor evening — a soft couch, dim lighting, headphones, maybe one or two close friends nearby. A sober tripsitter is genuinely a good idea, especially the first time. At higher doses, motor control gets wobbly and the world can fold in on itself, so going anywhere or operating anything mechanical is out of the question.
Dosing matters. The suggested range starts at 25–50 mg for a light experience, 50–100 mg for a moderate one, and 100–150 mg for a strong trip. Anything beyond 150 mg is heavy territory and not recommended. Because 2F-NENDCK is more potent than ketamine and its exact potency isn’t fully mapped, the universal advice from harm-reduction sources is the oldest one in the book: start low, go slow. The onset is fast enough that you’ll know within ten minutes whether you’ve taken enough, and the long duration is the real reason to be patient. Compulsive redosing is a known trap with this molecule, because the comedown feels gentler than ketamine’s and people often chase the peak. Resist that. Redosing too soon stacks effects in unpredictable ways and is when most bad experiences happen.
Combinations need extra care. Don’t mix with alcohol, opioids, benzodiazepines, or antidepressants. Don’t use if you have a history of psychosis, are pregnant or nursing, or are on prescription medication without checking interactions first. And because 2F-NENDCK shares a family with ketamine, the same long-term concerns may apply — bladder irritation and urinary discomfort are real risks with chronic dissociative use, so this is not a compound to lean on often. Spacing experiences out by weeks rather than days is the kinder path, both for your body and for the depth of the experience itself.
It’s also worth noting Leap doesn’t ship to Austria, the Czech Republic, or Germany, where local rules apply. In the UK it falls under the Psychoactive Substances Act. Legal status varies fast in this corner of the world, so checking your own jurisdiction is part of the homework.
Leap in the Bigger Picture
What makes Leap interesting isn’t just the molecule — it’s the kind of experience it represents. Classical psychedelics often demand something of you: a confrontation, a lesson, a story. Dissociatives like 2F-NENDCK ask for almost nothing. They simply turn down the volume on the self for a few hours and let you observe what’s left. That can be deeply restful, occasionally insightful, sometimes strange in ways that take a while to put into words.
In a psychedelic landscape increasingly framed by clinics, therapy, and clinical trials, Leap belongs to a different lineage. It’s part of the older, scrappier tradition of research chemicals — molecules that exist somewhere between curiosity and pharmacology, mapped by users rather than by institutions. That comes with a real responsibility. There’s less known about 2F-NENDCK than about psilocybin or LSD. The data is thinner. The long-term picture is still being drawn. That’s not a reason to avoid it, but it is a reason to approach it the way you’d approach any unfamiliar terrain — slowly, with respect, and with the right people around.
Leap won’t replace ketamine, and it isn’t trying to. It exists alongside it, longer-lasting and a little more dreamlike, less of a quick dive and more of a slow drift. For psychonauts who already know the dissociative space and want to explore a new shoreline within it, Leap offers exactly what its name promises: a step out, a quiet weightlessness, and a few hours of pure, simple escape.
